Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Homologous recombination DNA damage repair alterations (HRRalt) are linked to poorer outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) patients receiving standard treatments. This finding impacts future clinical trial design and patient counseling for advanced prostate cancer.
Area Of Science
- Oncology
- Genetics
- Prostate Cancer Research
Background
- Homologous recombination DNA damage repair (HRR) alterations are present in ~30% of advanced prostate cancer patients.
- HRR alterations are associated with worse prognosis in metastatic castrate-resistant prostate cancer.
- Limited data exist on HRR alterations' impact in metastatic hormone-sensitive prostate cancer (mHSPC).
Purpose Of The Study
- To investigate the association between HRR alterations and patient outcomes in mHSPC.
- To compare outcomes (time to castrate-resistance and overall survival) in mHSPC patients with and without HRR alterations.
- To provide real-world data informing clinical trial design and patient counseling.
Main Methods
- Utilized a de-identified US-based prostate cancer clinico-genomic database.
- Included patients with de novo mHSPC treated with intensified androgen deprivation therapy (ARPI or taxane).
- Analyzed time to castrate-resistance (TTCR) and overall survival (OS) using Cox proportional hazards models.
Main Results
- 181 out of 637 (28.4%) eligible patients had HRR alterations.
- HRR alterations were associated with less favorable TTCR for both ARPI (aHR 1.58) and taxane (aHR 1.77) treatments.
- Overall survival was directionally less favorable in patients with HRR alterations for both treatment types.
Conclusions
- This is the largest real-world study on HRR alterations in mHSPC outcomes.
- HRR alterations are associated with poorer outcomes in mHSPC patients treated with ARPI or taxanes.
- Findings can guide future clinical trial strategies and patient management.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...